Different platelet specificities of heparin-dependent platelet aggregating factors in heparin-associated immune thrombocytopenia

British Journal of Haematology
S L Pfueller, R David

Abstract

Delayed onset heparin-associated thrombocytopenia (HAT) is thought to be a result of formation of antiplatelet antibodies which cause platelet aggregation in the presence of heparin. Platelet aggregation in response to serum from patients with HAT has been studied in platelet-rich plasma (PRP) from a panel of normal blood donors. Heparin-dependent aggregation with any HAT serum occurred in PRP from only some donors. PRP from the non-responding donors did, however, aggregate in the presence of heparin with other HAT sera. The same patterns of aggregation or lack of response to HAT sera were seen in washed platelet suspensions. Heparin (0.06-2 U/ml) did not cause aggregation in the presence of normal serum with PRP from these donors. However, in PRP from four of the 17 individuals studied, heparin (0.25-1 U/ml) alone caused rapid platelet aggregation and some HAT sera heated at 56 degrees C caused platelet aggregation without added heparin. Sub-aggregating concentrations of adrenaline could replace heparin in promoting aggregation by heated HAT sera in PRP of the other donors. HAT IgG showed the same platelet specificities as the serum in causing either heparin- or adrenaline-dependent aggregation. Thus in HAT, antibodies are dir...Continue Reading

References

May 30, 1978·Archives of Orthopaedic and Trauma Surgery·P A RevellB V Roberts
Jul 29, 1976·The New England Journal of Medicine·R B BabcockW B Scharfman
Dec 1, 1976·Thrombosis Research·J N ShanbergeM Nakagawa
Nov 1, 1983·Annals of Internal Medicine·B K Phelan
Jan 1, 1980·The Journal of Clinical Investigation·E W SalzmanL Favreau
Apr 1, 1983·British Journal of Haematology·G O GogstadM B Krutnes
Dec 1, 1984·British Journal of Haematology·J van der LelieA E von dem Borne
Oct 1, 1984·American Journal of Hematology·H I SabaG A Morelli
Jan 1, 1984·Vox Sanguinis·B Boizard, J L Wautier
Apr 1, 1982·Seminars in Thrombosis and Hemostasis·C A Klein, M A Blajchman
Oct 2, 1980·The New England Journal of Medicine·D B CinesA D Schreiber
Aug 1, 1959·Proceedings of the Society for Experimental Biology and Medicine·T ISHIZAKA, K ISHIZAKA

❮ Previous
Next ❯

Citations

Jun 13, 2006·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·Emmanuel de MaistreDominique Lasne
Jan 1, 1993·Vox Sanguinis·A Greinacher, G Mueller-Eckhardt
Apr 1, 1992·Australian and New Zealand Journal of Medicine·B H Chong
Jan 1, 1991·Platelets·B H Chong
Sep 1, 1994·Baillière's Clinical Haematology·L A Harker, S R Hanson
Jan 1, 1987·Annals of the New York Academy of Sciences·J G Kelton, W G Murphy
Nov 13, 2001·Reviews in Clinical and Experimental Hematology·A GreinacherV Kiefel
Apr 11, 2001·Circulation·B E LewisUNKNOWN ARG-911 Study Investigators
Feb 1, 1989·Blut·B H Chong, M C Berndt
Mar 1, 1995·British Journal of Haematology·B H Chong
Nov 1, 1989·Stroke; a Journal of Cerebral Circulation·P S Becker, V T Miller
Nov 1, 1987·American Journal of Hematology·A M Shojania, G Turnbull

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.